← Leaderboards
Timothy Patrick Spicer
University Of Florida
$7,502,463
Attributed
$16,200,684
Total exposure
11
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,200,684 · 11
By mechanism
R01$11,475,153 · 4
R33$3,345,974 · 3
S10$645,395 · 2
R61$414,771 · 1
R56$319,391 · 1
Top collaborators
- Louis Daniel Scampavia14 shared
- Gavin R Rumbaugh13 shared
- Courtney A Miller9 shared
- Pietro P Sanna9 shared
- Theodore M Kamenecka4 shared
- Hugh Lee Sweeney4 shared
- Jarrod B French1 shared
Most similar at University Of Florida
Same institution · by research overlap
- Gavin R Rumbaugh$27,037,760
- Courtney A Miller$16,288,628
- Randall M. Golovin$232,480
- Hyo Kang$548,563
- Nigel Newbutt$455,026
Others in their field
Top investigators on “High Throughput Screening”
- Richard A Gibbs · Baylor College Of Medicine$250,166,309
- Leonard Freedman · Leidos Biomedical Research, Inc.$249,633,249
- David Heimbrook · Leidos Biomedical Research, Inc.$181,270,700
- Peter B. Gilbert · Fred Hutchinson Cancer Center$146,111,713
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
Research focus
High Throughput ScreeningDrug DiscoveryScreeningLibrariesPharmaceutical PreparationsIn VivoInnovationBaseCellsMiniaturizeMolecularSmall MoleculeValidationResponseScaffoldScale UpIn VitroAnimal ModelLeadBrainPropertyTherapeutic TargetNeuronsEnvironment
Grant awards (30)
An Innovative Approach to Identify Correctors of Metabolic Complications in HIV$925,072
R01 · FY2025 · DK
Identifying phosphoribosylformylglycinamidine synthase inhibitors as a new class of purine antimetabolites$549,474
R01 · FY2025 · CA
An Innovative Approach to Identify Correctors of Metabolic Complications in HIV$935,900
R01 · FY2024 · DK
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$475,793
R33 · FY2024 · NS
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$774,212
R01 · FY2023 · MH
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$497,954
R33 · FY2023 · NS
Identification of small molecules for neurological complications of HIV and substance abuse comorbidity$766,859
R01 · FY2022 · DA
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$547,173
R01 · FY2022 · MH
Identification of small molecules for neurological complications of HIV and substance abuse comorbidity$442,914
R01 · FY2022 · DA
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$295,695
R01 · FY2022 · MH
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$229,400
R61 · FY2022 · NS
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$185,371
R61 · FY2022 · NS
MaxCyte Scalable Transfection System$105,000
S10 · FY2022 · OD · contact PI
Identification of small molecules for neurological complications of HIV and substance abuse comorbidity$764,647
R01 · FY2021 · DA
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$652,164
R01 · FY2021 · MH
An Innovative Approach to Identify Correctors of Metabolic Complications in HIV$319,391
R56 · FY2021 · DK
Identification of small molecules for neurological complications of HIV and substance abuse comorbidity$740,742
R01 · FY2020 · DA
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$668,094
R01 · FY2020 · MH
Identification of small molecules for neurological complications of HIV and substance abuse comorbidity$785,874
R01 · FY2019 · DA
A Scalable Neuron-Based High-Throughput Screening Platform for the Discovery of Compounds that Restore Protein Expression Caused by Genetic Haploinsufficiency$686,767
R01 · FY2019 · MH
Advanced Development and Validation of 3 Dimensional Spheroid Culture of Primary Cancer Cells using Nano3D Technology$94,996
R33 · FY2019 · CA · contact PI
Identification of small molecules for neurological complications of HIV and substance abuse comorbidity$696,944
R01 · FY2018 · DA
A Scalable Neuron-Based High-Throughput Screening Platform for the Discovery of Compounds that Restore Protein Expression Caused by Genetic Haploinsufficiency$555,274
R01 · FY2018 · MH
Kinetic Imaging Plate Reader$540,395
S10 · FY2018 · OD · contact PI
Advanced Development and Validation of 3 Dimensional Spheroid Culture of Primary Cancer Cells using Nano3D Technology$460,385
R33 · FY2018 · CA · contact PI
Advanced Development and Validation of 3 Dimensional Spheroid Culture of Primary Cancer Cells using Nano3D Technology$94,996
R33 · FY2018 · CA · contact PI
A Scalable Neuron-Based High-Throughput Screening Platform for the Discovery of Compounds that Restore Protein Expression Caused by Genetic Haploinsufficiency$687,348
R01 · FY2017 · MH
Advanced Development and Validation of 3 Dimensional Spheroid Culture of Primary Cancer Cells using Nano3D Technology$475,865
R33 · FY2017 · CA · contact PI
"A Flexible and Scalable HTS Platform for CNS Probe Discovery"$744,559
R33 · FY2016 · NS
Advanced Development and Validation of 3 Dimensional Spheroid Culture of Primary Cancer Cells using Nano3D Technology$501,426
R33 · FY2016 · CA · contact PI